Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUETTE: Ceralasertib + Olaparib Maintenance in Ovarian Cancer
NCT04239014Phase 2Withdrawn
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of ceralasertib in Epithelial Ovarian Cancer (EOC), sponsored by AstraZeneca. Planned start Aug 2020; status: withdrawn.
02
Drugs
ceralasertib
03
Conditions
Epithelial Ovarian Cancer (EOC)
Beyond the preview
Go deeper on NCT04239014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239014.